I
n the past 5 years, tremendous progress has been made toward understanding suppressive mechanisms of T regulatory (Treg) 5 cells (1) (2) (3) (4) (5) . However, most of the investigations relied on naturally occurring or disease-associated Treg cells for these functional characterizations. It is now well accepted that Treg cells maintain peripheral tolerance and regulate autoimmunity (6 -10). However, circumstances under which this regulatory mechanism fails results in autoimmunity. Expansion of Treg cells is required to overcome the onset and progression of autoimmune disease. Recently, it has been shown that defined suppressive drugs (11) (12) (13) and hormones (14) , as well as anti-CD3 Ab (15) , can indeed expand Treg cells endowed with suppressive functions. However, these approaches may target both useful and pathogenic T cells limiting therapeutic application. Ag-specific strategies may circumvent these limitations, but approaches to expand specific Treg cells remains largely undefined.
Ig-proteolipid protein (PLP)1, an Ig molecule carrying the encephalitogenic PLP1 peptide corresponding to aa 139-151 of PLP efficiently internalizes into APCs via Fc␥Rs and augments loading of PLP1 peptide onto MHC class II molecules (16) . Consequently, presentation to T cells is enhanced by several orders of magnitude (16) . Upon aggregation, Ig-PLP1 acquires the additional property, namely cross-linking of Fc␥Rs, which result in IL-10 production by the APCs (17) . Ultimately, aggregated (agg) Ig-PLP1 was able to reverse ongoing experimental allergic encephalomyelitis (EAE), whether induced by a single epitope or by CNS homogenate containing multiple encephalitogenic determinants (16 -18) . Given that amelioration of disease was dependent upon IL-10 and this cytokine serves as growth factor for Treg cells (19, 20) , it is possible that agg Ig-PLP1 treatment mobilizes Treg cells for reversal of EAE. This study takes advantage of the agg Ig-PLP1/IL-10 system along with the PLP1-specific 5B6 TCR transgenic (Tg) mice (21, 22) to test whether agg Ig-PLP1 can induce expansion of Ag-specific Treg cells. Furthermore, the Treg cells were assessed for suppressive functions against EAE involving restricted as well as diverse T cell specificities. The findings indicate that in vivo exposure to adjuvant-free agg Ig-PLP1 drives naive 5B6 TCR Tg T cells to evolve as Treg cells expressing CD25, CTLA-4, and Foxp3, which produce IL-10. Moreover, these 5B6 Treg cells display suppressive function and reversed passive EAE induced in RAG-2 Ϫ/Ϫ SJL mice by transfer of 5B6 pathogenic T cells. Similarly, the 5B6 Treg cells reversed active EAE induced in the wild-type SJL/J mice with the cognate ligand PLP1 peptide. Interestingly, there was a broad efficacy against the disease, and these IL-10-producing Treg cells were able to display bystander suppression and reverse EAE induced in SJL/J mice with a CNS homogenate that likely incorporates multiple epitopes. However, intriguingly, the 5B6 Treg cells reversed EAE induced in F 1 (SJL/J ϫ C57BL/6) mice by the I-A s -restricted cognate PLP1 peptide but could not display bystander suppression and protect the F 1 animals against disease induced with the I-A b -restricted myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide (designated MOG peptide). The lack of bystander suppression was not due to strain restriction because the 5B6 Treg cells were unable to protect SJL/J mice against EAE mediated by myelin basic protein (MBP) 87-99 peptide (designated MBP3 peptide), which is restricted to the I-A s class II allele. However, when the T cells were preactivated in vitro with PLP1-loaded APCs, they became able to reverse MOG-induced disease in the F 1 similar to MBP3-induced EAE in SJL/J mice. Altogether, the results indicate that Treg cells would be able to overcome epitope spreading and reverse autoimmunity as long as the cognate Ag is available for activation.
Materials and Methods

Mice
SJL/J (H-2 s ) and C57BL/6 (H-2 b ) mice were purchased from The Jackson Laboratory and bred and maintained in our animal care facility for the duration of the experiments. F 1 mice were generated by crossing SJL/J males with C57BL/6 females. RAG-2-deficient (RAG-2 Ϫ/Ϫ ) SJL/J mice carrying PLP1-specific 5B6 TCR as transgene (H-2 s background) were described previously (21) . All experimental procedures were performed according to the guidelines of the institutional animal care committee.
Antigens
Peptides. The peptides used in this study were purchased from Metabion and purified by HPLC to Ͼ90% purity. PLP1 peptide (HSLGKWLGHP-DKF) encompasses amino acid residues 139-151 of PLP (23), PLP2 peptide includes amino acid residues 178-191(NTWTTCQSIAFPSK) of PLP (24) , and MBP3 peptide corresponds to amino acid residues 87-99 (VH-FFKNIVTPRTP) of MBP (25) . PLP1, PLP2, and MBP3 peptides are restricted to I-A s and are encephalitogenic in SJL/J (H-2 s ) mice (23) (24) (25) . MOG peptide (MEVGWYRSPFSRVVHLYRNGK) containing amino acid residues 35-55 of MOG is restricted to I-A b and is encephalitogenic in C57BL/6 mice (26). Ig chimeras. The Ig chimeras used in this study are described in Table I . All chimeras carry the corresponding peptide within the H chain CDR3 region. Ig-W is the parental Ig not encompassing any myelin or other peptide. All chimera transfectants were grown up in large-scale culture of DMEM containing 10% iron-enriched calf serum (HyClone). The chimeras were purified from culture supernatant on affinity chromatography columns made of rat anti-mouse -chain coupled to CNBr-activated Sepharose 4B (Amersham Biosciences). To avoid cross-contamination, separate columns were used to purify each chimera. Aggregation of the Ig chimeras was done using 50%-saturated (NH 4 ) 2 SO 4 as described previously (17) . Because all the Ig chimeras were derived from the same Ig backbone and thereby comprise identical IgG2b isotype, their Fc␥Rs will be similar. In this respect, we may refer to them indistinguishably as Ig chimeras. CNS homogenate. Frozen unstripped rat brains (Pelfreez Biologicals) were homogenized in PBS using a Waring blender and adjusted to 300 mg/ml with PBS as described previously (17) .
Expansion and isolation of Treg cells
Expansion of specific Treg cells was conducted in two ways. SJL/J mice recipient of 5 ϫ 10 6 splenic CD4 ϩ T cells from RAG-2 Ϫ/Ϫ 5B6 TCR Tg SJL mice were given an i.p. injection of 300 g of agg Ig-PLP1 on days 4, 8, and 12 posttransfer. The mice were sacrificed, and their spleens were used for purification of Treg cells. For expansion of Treg cells in RAG-2 Ϫ/Ϫ 5B6 TCR Tg SJL mice, three injections of 300 g of agg Ig-PLP1 were given at 4-day intervals, and the splenic Treg cells were isolated 10 days after the final injection. In both regimens, the Treg cells were detectable at day 7, but higher levels of CD4 ϩ CD25 ϩ were observed at day 10. Thus, purification of Treg cells from the spleen was performed on day 10 by depleting CD4 Ϫ cells using Miltenyi Biotec's CD4 ϩ isolation kit, and the CD4 ϩ CD25 ϩ T cells were isolated on anti-CD25 microbeads, according to Miltenyi Biotec's instructions. The purity of cells is usually 90 -95%.
Flow cytometry for analysis of the phenotype of Treg cells
Splenic CD4
ϩ T cells were isolated by MACS using anti-CD4 microbeads, according to Miltenyi Biotec's instructions, and then stained with PE-conjugated anti-CTLA-4 Ab (UC10-4F10-11) or control hamster IgG at 37°C for 2 h. Subsequently, the cells were incubated with FITC-conjugated anti-TCR-V␤6 (RR4-7), APC-conjugated anti-CD25 (PC61), and PE-Cy5-conjugated anti-CD4 (H129.19) Abs at 4°C for 30 min. The cells were then washed and analyzed using a FACSVantage flow cytometer and the CellQuest software (BD Biosciences). Dead cells were excluded based on their forward and side scatter profiles.
Real-time PCR analysis for Foxp3 expression
Total RNA was extracted from both CD4 ϩ CD25 ϩ and CD4 ϩ CD25 Ϫ T cells using TRIzol reagent. The relative mRNA levels of forkhead/winged helix transcription factor gene (Foxp3) was determined by real-time PCR using 300 ng of RNA, 0.5 M Foxp3 or ␤-actin primers, and the QuantiTect SYBR Green Real-Time PCR kit from Qiagen as described previously (30) . The Foxp3 and ␤-actin primers were described previously (31) .
Measurement of IL-10 by ELISA
Cytokine secretion by Treg cells was performed by incubating the purified cells (5 ϫ 10 4 /well) on anti-CD3 Ab (2C11)-coated plates (10 g/ml) and measuring IL-10 48 h later by ELISA, according to the standard protocol of BD Pharmingen. The capture Ab was JES5-2A5, and the biotinylated Ab was JES5-16E3. Recombinant mouse IL-10 was used in all experiments for construction of standard curves. The cytokine concentration in culture supernatants was interpolated from the linear portion of the standard curve. The use of anti-CD3 Ab instead of peptide and APCs to stimulate the purified Treg cells is to ensure that IL-10 is produced by the Treg cells rather than APCs.
Proliferation assay
Proliferation assays were performed as described previously (31 
Induction of EAE
Active EAE. This was done as described previously (17) . Briefly, mice (6-8 wk old) were induced for EAE by s.c. injection in the footpads and at the base of the limbs of a 200-l IFA/PBS (v/v) solution containing 6 mg of CNS homogenate and 200 g of Mycobacterium tuberculosis H37Ra (Difco). Six hours later, the mice were given i.v. 200 ng of purified Bordetella Pertussis toxin (List Biological Laboratories). A second injection of B. Pertussis toxin was given after 48 h. The mice were then scored daily for clinical signs of EAE as follows: 0, no clinical score; 1, loss of tail tone; 2, hind limb weakness; 3, hind limb paralysis; 4, forelimb paralysis; and 5, moribund or death.
A similar protocol was used for induction of active EAE with PLP1, PLP2, MBP3, and MOG peptides, which were used at 100, 100, 200, and 300 g/injection, respectively. Pertussis toxin was used at 75 ng for PLP1 or PLP2 peptide, 200 ng for MBP3 peptide, and 500 ng for MOG peptide. Passive EAE. Six-to 8-week-old RAG-2 Ϫ/Ϫ SJL/J mice were induced for EAE by transfer of 1 ϫ 10 6 naive 5B6 TCR Tg T cells. These cells do not require activation before transfer into the RAG-2 Ϫ/Ϫ SJL/J hosts. Also, Pertussis toxin is not required for the development of EAE.
Suppression of EAE with Treg cells
For active EAE 1 ϫ 10 6 purified CD4 ϩ CD25 ϩ T cells were adoptively transferred into SJL/J mice 3 days after or 1 day before induction of EAE as indicated. For suppression of passive EAE, 0.5 ϫ 10 6 CD4 ϩ CD25 ϩ T cells were given to RAG-2 Ϫ/Ϫ SJL mice i.v. along with naive 5B6 TCR Tg T cells. Thereafter, the animals were monitored for clinical signs of EAE.
For neutralization of IL-10 during disease suppression by Treg cells, the SJL/J mice received CD4 ϩ CD25 ϩ 5B6 Treg cells 1 day before induction of EAE with PLP1 peptide and were given i.p. 300 g/mouse of purified anti-IL-10 Ab (JESS-2A5) on days 9, 13, and 17 postdisease induction.
Treatment of EAE with agg Ig chimeras
For treatment of disease with agg Ig chimeras, the mice were induced for EAE with CNS homogenate and then given i.p. 300 g/mouse agg Ig chimera in 300 l of PBS on days 9, 13, and 17 postdisease induction. The mice then continued to be monitored for clinical signs of EAE.
Depletion of CD25 ϩ T cells in vivo
For depletion of CD25 ϩ T cells, the mice were given i.p. two injections of anti-CD25 Ab (PC61) 4 and 2 days before the induction of disease with 6 mg of CNS homogenate. Each injection consisted of 500 l of PBS containing 1 mg of anti-CD25 Ab. A group of mice received 1 mg of rat IgG instead of anti-CD25 Ab to serve as control. The animals were then subjected to agg Ig chimera treatment regimen as described above.
Activation of Treg cells
For activation of Treg cells before injection to animals, the cells (0.5 ϫ 10 6 cells/ml) were incubated with irradiated (3000 rad) SJL splenocytes (1.5 ϫ 10 6 cells/ml) and 30 g/ml PLP1 peptide. After 24 h, the excess peptide was washed out, and the activated Treg cells were injected into mice.
Statistical analysis
All analysis for statistically significant differences was performed with Student's paired t test. A value of p Ͻ 0.05 is considered significant.
Results
Exposure to agg Ig-PLP1 drives PLP1-specific 5B6 TCR Tg T cells into Treg cells
SJL/J mice recipient of PLP1-specific 5B6 TCR (V␤6 ϩ ) Tg T cells and treated with agg Ig-PLP1 increase both CD25 and CTLA-4 expression on their V␤6 ϩ T cells ( Fig. 1) . In fact, the number of V␤6 ϩ CD4 ϩ cells expressing CD25 was 6 -8% in untreated or sol Ig-PLP1-treated 5B6-recipient SJL mice but increased to 13.6% in animals given agg Ig-PLP1. Similarly, CTLA-4 expression on V␤6 ϩ CD4 ϩ CD25 ϩ cells rose from 6 to 10% in untreated or sol Ig-PLP1-treated 5B6-recipient SJL mice to 41% in the mice treated with the agg Ig-PLP1. Of note, the number of V␤6 ϩ CD4 ϩ T cells was similar in SJL and SJL/5B6 mice despite the fact that the latter received 5 ϫ 10 6 5B6 cells. This may be due to T cell homeostasis.
Similar results were obtained when agg Ig-PLP1 treatment was applied to the RAG-2 Ϫ/Ϫ 5B6 TCR Tg SJL/J mice (Table II) 
CD25
ϩ had CTLA-4. In contrast, the mice treated with agg Ig-PLP1 increased their CD25 expression to 21.3%, and among these V␤6
ϩ cells, 42.2% had CTLA-4 on the surface. Overall, these results indicate that treatment with agg Ig-PLP1 increases CD25 and CTLA-4 expression on PLP1-specific TCR Tg T cells in vivo.
The Ag-specific V␤6 ϩ CD4 ϩ CD25 ϩ were purified and tested for Foxp3 mRNA expression. Fig. 2A shows that cells isolated from 5B6 Tg or SJL mice recipient of 5B6 T cells (SJL/5B6) had approximately a 4-fold increase in Foxp3 mRNA expression, whereas V␤6
Ϫ counterparts had no such increase. Also, the cells produced significant amounts of IL-10 relative to the CD25 Ϫ counterparts when they were stimulated with plate-bound anti-CD3 Ab ( 
Ag-specific Treg cells suppress both active and passive EAE
Because the agg Ig-PLP1-expanded 5B6 TCR Tg Treg cells were able to suppress their CD25
Ϫ counterparts in vitro, we sought to test whether such suppressive functions could be operative against EAE induced by PLP1 peptide and thus mediated by polyclonal PLP1-specific pathogenic T cells. As can be seen in Fig. 3 , transfer of 5B6 TCR Tg Treg cells 3 days after induction of EAE had minimal effects on the severity of the initial phase of disease relative to mice that did not receive any transfer (Fig. 3A) . However, the clinical relapses usually associated with PLP1-induced EAE, which were evident in the mice recipient of no transfer, were not observed for the 60-day monitoring period. Moreover, when the transfer was performed 1 day before disease induction, the initial phase of EAE was reduced significantly with a mean maximal score of 1.1 Ϯ 0.7, and the relapses were completely inhibited (Fig. 3B ). This is a significant protection against the disease because mice without Treg transfer had a mean maximal clinical score of 3.0 Ϯ 0.5 during the acute phase of EAE and had clinical relapses typical of PLP1-induced EAE.
It has been shown previously that naive 5B6 TCR Tg SJL/J mice develop spontaneous EAE (21) . In the present study, we found that transfer of naive 5B6 TCR Tg T cells into RAG-2 Ϫ/Ϫ SJL mice induces severe EAE that ultimately leads to animal death (Fig.  3C ). This passive EAE system was then used to test the 5B6 TCR Tg Treg cells for suppressive functions. As can be seen in Fig. 3C , the mice recipient of naive 5B6 TCR Tg T cells had a disease onset at day 12 posttransfer with a rapid heightening of the clinical scores, leading to 33% mortality and a mean maximal score of 4.0 Ϯ 0.5. The animals were unable to recover by day 70 and were thus sacrificed. Transfer of CD4 ϩ CD25 ϩ 5B6 TCR Tg Treg cells into these mice significantly reduced the severity of the disease, and the mean maximal score was 1.6 Ϯ 1.1. Also, no death was observed in this group of mice, and recovery was achieved by day 20 after T cell transfer. The suppressive functions of 5B6 Treg cells seem to be dependent partially on IL-10 as mice recipient of Treg cells 1 day before induction of EAE and given anti-IL-10 Ab restored the severity of their acute disease phase relative to animals that did not receive anti-IL-10 Ab (Fig. 3D ) or mice that received Treg cells and rat IgG isotype control (data not shown). Overall, these results indicate that agg Ig-PLP1-expanded 5B6 Treg cells display effective suppressive functions against both active and passive EAE.
Treg cells induced by a single epitope reverse EAE involving diverse specificities
Experiments were set up to determine whether expansion of protective Treg cells is unique to Ig-PLP1 or other chimeras carrying different myelin epitopes could also expand similar protective Treg cells. PLP2 and MBP3 peptides were chosen for these studies because of their encephalitogenicity in SJL/J mice and the fact that the respective Ig-PLP2 and Ig-MBP3 chimeras are available. However, given that TCR Tg mice are not available for PLP2 and MBP3 peptides, we opted to test Ig-PLP2 and Ig-MBP3 rather directly and assessed whether suppression of disease by the chimeras is dependent on Treg cells. Furthermore, because the Treg cells expanded by Ig-PLP1 produce IL-10, bystander suppression could be operative, and protection should be possible against disease involving diverse T cell specificities. Thus, the chimeras were tested initially for amelioration of EAE induced with a CNS homogenate incorporating multiple T cells epitopes and presumably involving diverse T cells specificities. As can be seen in Fig. 4 , mice induced for EAE with a CNS homogenate had a severe phase of paralysis with a mean maximal score of 2.4 Ϯ 0.5, and the control agg Ig-W, the parental chimera not encompassing any myelin peptide, did not have any effect on ameliorating the disease. Treatment with agg Ig-PLP1 reduced the mean maximal score to 1.5 Ϯ 0.4, and full recovery was achieved by day 25 postdisease induction (Fig. 4B ). This effect is specific because Ig-W had no a Adult (6 -8 wk) RAG2 Ϫ/Ϫ 5B6 TCR Tg SJL mice were given an injection of 300 g of agg Ig-PLP1 on days 0, 4, and 8, and the splenic CD4 T cells were isolated 10 days after the final injection. The cells (2 ϫ 10 6 cells/sample) were analyzed for cell surface expression of V␤6, CD25, and CTLA-4 by flow cytometry as described in Fig. 1 . A group of untreated mice (Nil) was included for control purposes.
b The cells were gated on CD4 and V␤6, and analyzed for CD25 expression. c The cells were gated on CD4, V␤6, and CD25, and analyzed for CTLA-4 expression.
d Mean Ϯ SD of 10 -15 mice.
FIGURE 2. Agg Ig-PLP1-expanded CD4
ϩ CD25 ϩ T cells produce IL-10 and suppress proliferative responses of their CD4 ϩ CD25 Ϫ counterparts. Purified PLP1-specific CD4
ϩ CD25 ϩ T cells tested for expression of Foxp3 mRNA expression (A), IL-10 production (B), and suppression of their CD4 ϩ CD25 Ϫ counterparts (C). CD4 ϩ CD25 ϩ and CD4 ϩ CD25 Ϫ cells were purified from the spleens of agg Ig-PLP1-treated 5B6 Tg mice (5B6 Tg) or SJL animals recipient of 5B6 CD4 T cells (SJL/5B6). Each group included five mice. RNA was extracted from 1 ϫ 10 5 cells by the TRIzol method, and 300 ng were used for analysis of Foxp3 expression by comparative real-time PCR. Because Foxp3 expression was similar in both populations, only cells from 5B6 Tg mice were used for IL-10 and proliferation assays. IL-10 production assays used 2 ϫ 10 5 cells that were stimulated with plate-bound anti-CD3 Ab or rat IgG isotype control (10 g/ml) for 48 h. Measurement of IL-10 was conducted by ELISA. The proliferation assays in C used 2 ϫ 10 5 T cells and 1 ϫ 10 5 SJL-irradiated (3000 rad) splenocytes as APCs. For coculture assays, the T cell number was 1 ϫ significant effects on the disease, and the clinical signs of EAE were similar to those observed in untreated (Nil) animals (Fig. 4A) . Ig-PLP2 (containing PLP178-191) as well as Ig-MBP3 (incorporating MBP87-99) had significant effects on the disease and reduced the severity of EAE in a fashion similar to agg Ig-PLP1 (Fig.  4, C and D) . Indeed, the mean maximal disease score was reduced from 2.4 Ϯ 0.5 in the untreated group to 1.4 Ϯ 0.4 and 1.4 Ϯ 0.5 in mice treated with agg Ig-PLP2 and agg Ig-MBP3, respectively. Also, in both groups, recovery from the initial phase of disease was achieved on day 20 postdisease induction for agg Ig-PLP2-treated mice and on day 22 for those given Ig-MBP3.
To assess for involvement of Treg cells in the protection against EAE, the SJL/J mice were given anti-CD25 Ab to deplete Treg cells before EAE induction with CNS homogenate and then treated with agg Ig chimera and monitored for clinical signs of EAE. The results indicate that depletion of Treg cells by anti-CD25 Ab nullifies the suppressive function of Ig-PLP1 (Fig. 5A) , Ig-PLP2 (Fig.  5B) , and Ig-MBP3 (Fig. 5C) , and the disease was restored to full severity like untreated mice. Rat IgG used instead of anti-CD25 Ab did not restore disease severity, and the clinical signs of EAE were reduced by treatment with the Ig-PLP1 (Fig. 5A) . In fact, the mean maximal clinical score in this group was ϳ1.4 like the undepleted but Ig-PLP1 treated mice (compare with Fig. 4) . Overall, these results indicate that Treg cells are required for modulation of disease involving diverse T cell specificities and raise the question of how Treg cells expanded by a single epitope display broad suppression against diverse disease.
Requirement for Ag-induced activation for Treg cells to display intermolecular bystander suppression
To investigate the mechanism underlying broad suppression of disease by Treg cells, we began by testing I-A s -restricted, PLP1-specific 5B6 Treg cells for suppression of intermolecular EAE induced by I-A b -restricted MOG peptide. Accordingly, 5B6 Treg cells were expanded in RAG-2 Ϫ/Ϫ 5B6 TCR Tg SJL/J mice with agg Ig-PLP1, transferred into F 1 (SJL/J ϫ C57BL/6) mice, and tested for suppression of EAE induced 1 day later in the hosts by I-A b -restricted MOG peptide. Fig. 6 shows that transfer of 5B6 TCR Tg Treg cells significantly reduced the severity of PLP1-induced EAE in the F 1 mice (Fig. 6A) . Indeed, while the recipients of Treg cells had a mean maximal clinical score of 1.0 Ϯ 0.4 and fully recovered by day 30 postdisease induction, those who did not receive transfer of Treg cells had a 3.1 Ϯ 0.2 mean maximal score and did not fully recover for the 60-day clinical monitoring period. In contrast, when the F 1 mice were induced for EAE with MOG peptide, the 5B6 Treg cells had no effect on the disease, and the mice had similar pattern of clinical EAE as those without Treg transfer (Fig. 6B) . These results indicate that suppressive functions by Treg cells operate in an Ag-restricted manner. This observation was surprising given that Treg cells produce IL-10, which should be able to mediate bystander suppression. Given the possibility that genetic dilution of I-A s may interfere with Ag presentation and Treg function, we sought to test the 5B6 Treg cells for suppression of EAE induced by an intramolecular PLP2 peptide as well as an intermolecular MBP3 peptide but in the SJL/J rather than F 1 mice. Accordingly, SJL/J mice were given PLP1-specific 5B6 TCR Tg Treg cells and 1 day later induced for EAE with PLP2 or MBP3 peptide or CNS homogenate and monitored for clinical signs of EAE. As can be seen in Fig. 7 , transfer of PLP1-specific Treg cells reduced the severity of EAE when the disease was induced by CNS homogenate or PLP2 peptide (Fig. 7, A and B) . However, when MBP3 peptide was used for EAE induction, there was only minimal reduction in disease severity (Fig. 7C) . Thus, Treg cells display intra-(PLP2) but not intermolecular (MBP3 and MOG) suppressive functions unless the specific Ag was provided during disease induction, as is the case for CNS homogenate.
These observations suggest that activation with a specific Ag may be required for Treg cells to exercise broad suppressive functions. To test this postulate, 5B6 TCR Tg Treg cells were activated in vitro by stimulation with PLP1 peptide presented on splenic APCs, transferred to mice, and the hosts were induced for EAE and monitored for clinical signs of the disease. As can be seen in Fig. 8 , the activated Treg cells have become effective not only against MBP3-induced EAE in SJL/J mice but also against MOGinduced disease in F 1 animals. Indeed, the mean maximal score of disease severity in SJL/J mice induced for EAE with MBP3 peptide was reduced from 2.3 Ϯ 0.5 to 0.9 Ϯ 0.4 when the animals received preactivated Treg cells (Fig. 8B and Table III ). This is much more significant than the reduction observed with nonactivated Treg cells (Table III) . Also, the mean maximal score of disease severity was decreased from 2.8 Ϯ 0.5 to 1.8 Ϯ 0.5 when the F 1 mice induced for EAE with MOG peptide received the preactivated 5B6 Treg cells ( Fig. 8D and Table III ). This is also more significant than the reduction of severity obtained with nonactivated Treg cells (Table III) . In fact, the animals recovered on day 30 postdisease induction in the case of preactivated Treg transfer while recovery was not achieved when the mice received no Treg transfer or transfer of nonactivated Treg cells (Table III) . The preactivation of Treg cells had less effect on CNS as well as PLP2-induced EAE relative to nonpreactivated Treg cells. As such, in the animals induced with the CNS homogenate, the mean maximal score of disease severity was 1.8 Ϯ 0.4 with nonpreactivated Treg cells and decreased to 1.6 Ϯ 0.5 when the Treg cells were preactivated (Table III) . Similarly, when EAE was induced with PLP2 peptide, the mean maximal score was 1.8 with nonpreactivated Treg cells and decreased to 1.2 Ϯ 0.8 when the Treg cells were preactivated in vitro. Taken together, these results indicate that activation of the Treg cells is required for broad suppressive function.
Discussion
The studies presented in this article defined an approach for expansion of Ag-specific Treg cells and explored the requirements for broad suppressive functions against autoimmunity involving diverse pathogenic T cell specificities. The findings indicated that injection of adjuvant-free agg Ig-PLP1 into mice drives 5B6 TCR Tg T cells into Treg cells expressing CD4, CD25, and CTLA-4 ( Fig. 1 and Table II) . Moreover, these cells had increased FoxP3 mRNA were nonproliferative and produced IL-10 ( Fig. 2) . This Treg phenotype is supported by a display of suppressive functions as proliferation of CD4 ϩ CD25 Ϫ TCR Tg 5B6 counterparts was reduced significantly by the CD4 ϩ CD25 ϩ 5B6 cells (Fig. 2) . Taken together, these results indicate that exposure to adjuvantfree agg Ig-PLP1 drives 5B6 TCR Tg T cells to differentiate into IL-10-producing Treg cells. The soluble form of Ig-PLP1 was less effective in expanding 5B6 Treg cells, and this likely suggests that IL-10 produced by APCs upon Fc␥R cross-linking by agg Ig-PLP1 (17) contributed to the expansion of Treg cells. This is in good agreement with prior studies suggesting that IL-10 serves as growth factor for development of Treg cells (19, 20) . Furthermore, these PLP1-specific 5B6 TCR Tg Treg cells suppress both active and passive EAE involving a single (PLP1) T cell specificity, and such function was IL-10 dependent (Fig. 3) . However, surprisingly, the 5B6 TCR Tg Treg cells were unable to ameliorate MOGinduced EAE in F 1 mice or MBP3-mediated EAE in SJL/J animals despite the ability of suppressing PLP2-or even CNS homogenateinduced EAE (Figs. 6 and 7 ). These observations have led us to believe that Ag-induced activation is required for the 5B6 Treg cells to display broad suppressive functions. Indeed, induction of disease with CNS homogenate would activate diverse T cells, leading to exposure of most myelin proteins, including PLP. In this case, PLP1 peptide would be available and the Treg cells would be a Agg Ig-PLP1-expanded 5B6 TCR Tg Treg cells were stimulated with 30 g/ml PLP1 peptide presented on irradiated SJL/J APC splenocytes, and 24 h later, 1 ϫ 10 6 activated Treg cells were transferred into groups (five to six mice per group) of SJL/J or (SJL/J ϫ C57BL/6) F 1 mice. Three days later, the mice were induced for EAE with the indicated autoantigen as described in the legend to Fig. 8 . Groups of animals that received nonactivated 5B6 TCR Tg Treg cells as well as mice that did not receive Treg transfer (Nil) were included for control purposes. The animals were scored daily for clinical signs of EAE.
b Highest daily mean clinical score observed during the entire monitoring period of time.
c The day on which the mean clinical score is Յ0. activated, produce IL-10, and in turn display bystander suppression. Similarly, induction of disease with PLP2 peptide would also expose PLP, which encompasses PLP1 peptide and thereby triggers activation of the Treg cells. However, exposure and presentation of PLP1 peptide may not occur when the disease is induced by MOG or MPB3 peptide, particularly because epitope spreading (32) has been shown to follow a sequential order (33) . When these PLP1-specific Treg cells were activated in vitro by stimulation with PLP1 presented on splenic APCs, suppression of MOG-EAE in F 1 mice as well as MBP3-EAE in SJL/J mice was observed ( Fig.  8 and Table III) . These results agree with previous report, suggesting that activation would be required for in vivo Treg-suppressive function (34) . Also, the data presented in Fig. 4 showing that the severity of CNS-induced EAE can be reduced by diverse chimeras carrying a single myelin epitope support the notion that activation is required for Treg cells to display broad suppressive function. The likely scenario here could be that during induction of disease with CNS homogenate pathogenic and regulatory T cells are triggered. Treatment with the chimeras under noninflammatory circumstances would sustain activation and expansion of Treg cells but not pathogenic cells. Consequently, cytokine production by Treg cells is in motion promoting bystander suppression of disease involving multiple pathogenic specificities. In fact, when anti-CD25 Ab was injected to deplete Treg cells before induction of disease, the treatment with the Ig chimeras failed to reduce the severity of disease (Fig. 5) .
The first point to be taken from these studies is that a regimen was defined that is as effective as other strategies (35, 36) for expansion of Treg cells but would be rather practical for amelioration of autoimmunity. Moreover, because the regimen involves Ags, the Treg cells would be of defined specificity rather than polyclonally activated cells (11) (12) (13) 15) . The second point is that reactivation of Treg cells triggers cytokine production and overrides restriction for specificity. This may be the underlying mechanism for the controversial observations regarding specificity of Treg-suppressive function (14, 34, 37, 38) . Also, a similar mechanism could be responsible for the differential Treg function associated with their activation status (39) . Finally, the studies parallel with other observations demonstrating the potency of Treg cells expanded with a single epitope against autoimmunity involving diverse T cell specificities (40 -42) .
Agg Ig-peptide chimeras provide a means to expand Treg cells with specificity, which hitherto has not been possible, and convert potentially pathogenic T cells into a regulatory T cells as exemplified by the effect of agg Ig-PLP1 on the encephalitogenic TCR Tg 5B6 T cells.
